LH
Labcorp Holdings Inc. NYSE Listed Mar 29, 1990$270.08
+1.85%
vs $265.18
Mkt Cap $22.1B
52w Low $241.81
54.5% of range
52w High $293.72
50d MA $260.76
200d MA $267.24
P/E (TTM)
23.6x
EV/EBITDA
13.3x
P/B
2.6x
Debt/Equity
0.8x
ROE
10.2%
P/FCF
18.8x
RSI (14)
56.50
ATR (14)
$5.96
Beta
0.98
50d MA
$260.76
200d MA
$267.24
Avg Volume
591.1K
Labcorp Holdings, Inc. provides laboratory services to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
358 South Main Street · Burlington, NC 27215 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | BMO | 4.09 | 4.25 | +3.9% | 257.14 | +2.9% | -0.1% | -0.4% | -1.1% | +1.6% | -0.1% | — |
| Feb 17, 2026 | BMO | 3.95 | 4.07 | +3.0% | 282.63 | -1.7% | -2.1% | +0.8% | +1.3% | +0.1% | +0.9% | — |
| Oct 28, 2025 | BMO | 4.13 | 4.18 | +1.2% | 275.66 | -3.9% | -5.8% | -4.4% | +1.7% | +0.6% | +1.5% | — |
| Jul 24, 2025 | BMO | 4.17 | 4.35 | +4.3% | 250.51 | +6.4% | +6.9% | -1.0% | -1.2% | -0.1% | +0.8% | — |
| Apr 29, 2025 | BMO | 3.74 | 3.84 | +2.7% | 229.60 | -3.4% | +4.7% | +0.2% | +0.1% | +2.6% | -0.3% | — |
| Feb 6, 2025 | BMO | 3.39 | 3.45 | +1.8% | 249.99 | +1.2% | -0.9% | -0.6% | -0.5% | +0.0% | -1.6% | — |
| Oct 24, 2024 | BMO | 3.47 | 3.50 | +0.9% | 219.90 | +2.6% | +4.6% | -0.6% | -0.5% | +0.3% | +1.1% | — |
| Aug 1, 2024 | BMO | 3.78 | 3.94 | +4.2% | 215.44 | +2.1% | +8.3% | +1.1% | -3.1% | -1.2% | -2.9% | — |
| Apr 25, 2024 | BMO | 3.48 | 3.68 | +5.7% | 207.94 | -1.5% | -4.6% | +0.0% | +2.9% | -1.4% | -0.0% | — |
| Feb 15, 2024 | BMO | 3.29 | 3.30 | +0.3% | 228.11 | -0.5% | -2.6% | -2.5% | -0.4% | +1.0% | -0.1% | — |
| Oct 26, 2023 | BMO | 3.37 | 3.38 | +0.3% | 197.69 | +0.9% | +4.2% | -3.4% | -0.4% | +0.8% | +2.1% | — |
| Jul 27, 2023 | BMO | 3.47 | 3.42 | -1.4% | 218.84 | -1.7% | -1.3% | -0.7% | -0.3% | -0.1% | +0.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $269.17 | $271.95 | +1.0% | +2.1% | -0.5% | -4.5% | +1.2% | +1.8% |
| Feb 24 | Piper Sandler | Maintains | Neutral → Neutral | — | $285.30 | $285.20 | -0.0% | +0.6% | -1.5% | +1.7% | +0.5% | -0.9% |
| Feb 18 | JP Morgan | Maintains | Overweight → Overweight | — | $276.67 | $279.37 | +1.0% | +0.8% | +1.3% | +0.1% | +0.9% | +0.6% |
| Feb 18 | Baird | Maintains | Outperform → Outperform | — | $276.67 | $279.37 | +1.0% | +0.8% | +1.3% | +0.1% | +0.9% | +0.6% |
| Feb 6 | JP Morgan | Maintains | Overweight → Overweight | — | $278.23 | $280.00 | +0.6% | -0.4% | -1.2% | +3.8% | +1.9% | -4.1% |
| Nov 7 | JP Morgan | Maintains | Overweight → Overweight | — | $246.64 | $246.84 | +0.1% | +2.5% | +3.3% | +2.7% | -0.8% | +0.7% |
| Oct 29 | UBS | Maintains | Buy → Buy | — | $259.69 | $259.00 | -0.3% | -4.4% | +1.7% | +0.6% | +1.5% | -2.1% |
| Oct 17 | Mizuho | Maintains | Outperform → Outperform | — | $283.71 | $284.68 | +0.3% | +0.8% | +1.7% | -2.3% | -0.5% | +0.4% |
| Oct 17 | UBS | Maintains | Buy → Buy | — | $283.71 | $284.68 | +0.3% | +0.8% | +1.7% | -2.3% | -0.5% | +0.4% |
| Oct 3 | Evercore ISI | Maintains | Outperform → Outperform | — | $279.44 | $279.96 | +0.2% | -0.9% | -0.7% | +1.7% | -0.8% | +0.1% |
| Oct 2 | Barclays | Maintains | Equal Weight → Equal Weight | — | $279.06 | $277.84 | -0.4% | +0.1% | -0.9% | -0.7% | +1.7% | -0.8% |
| Jul 25 | Truist | Maintains | Buy → Buy | — | $267.69 | $268.04 | +0.1% | -1.0% | -1.2% | -0.1% | +0.8% | -1.5% |
| Jul 25 | Evercore ISI | Maintains | Outperform → Outperform | — | $267.69 | $268.04 | +0.1% | -1.0% | -1.2% | -0.1% | +0.8% | -1.5% |
| Jul 25 | Morgan Stanley | Maintains | Overweight → Overweight | — | $267.69 | $268.04 | +0.1% | -1.0% | -1.2% | -0.1% | +0.8% | -1.5% |
| Jul 25 | UBS | Maintains | Buy → Buy | — | $267.69 | $268.04 | +0.1% | -1.0% | -1.2% | -0.1% | +0.8% | -1.5% |
| Jul 25 | Baird | Maintains | Outperform → Outperform | — | $267.69 | $268.04 | +0.1% | -1.0% | -1.2% | -0.1% | +0.8% | -1.5% |
| Jul 18 | UBS | Maintains | Buy → Buy | — | $247.24 | $247.82 | +0.2% | -1.4% | -0.3% | +3.7% | -0.6% | +6.9% |
| Jul 9 | Evercore ISI | Maintains | Outperform → Outperform | — | $257.45 | $260.01 | +1.0% | +0.6% | -2.1% | -1.6% | +0.1% | -1.7% |
| Jun 25 | Barclays | Maintains | Equal Weight → Equal Weight | — | $262.53 | $261.73 | -0.3% | -1.5% | -0.7% | +1.4% | +0.7% | +0.7% |
| Jun 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $259.37 | $260.00 | +0.2% | +0.2% | +0.7% | -0.2% | +1.1% | -1.7% |
| May 12 | Truist | Maintains | Buy → Buy | — | $245.73 | $248.73 | +1.2% | +2.1% | -0.4% | -3.1% | +1.6% | +1.3% |
| May 6 | Piper Sandler | Maintains | Neutral → Neutral | — | $246.82 | $245.05 | -0.7% | -1.2% | +0.8% | +1.2% | -1.2% | +2.1% |
| Apr 30 | Barclays | Maintains | Equal Weight → Equal Weight | — | $240.42 | $239.32 | -0.5% | +0.2% | +0.1% | +2.6% | -0.3% | -1.2% |
| Apr 30 | Baird | Maintains | Outperform → Outperform | — | $240.42 | $239.32 | -0.5% | +0.2% | +0.1% | +2.6% | -0.3% | -1.2% |
| Apr 11 | Truist | Maintains | Buy → Buy | — | $218.61 | $218.15 | -0.2% | +1.3% | +3.0% | -0.9% | -2.4% | -1.6% |
| Apr 10 | Barclays | Maintains | Equal Weight → Equal Weight | — | $230.48 | $228.66 | -0.8% | -5.2% | +1.3% | +3.0% | -0.9% | -2.4% |
| Mar 4 | Citigroup | Upgrade | Neutral → Buy | — | $254.04 | $257.00 | +1.2% | +1.1% | -1.0% | -0.1% | -0.4% | -3.5% |
| Feb 10 | Piper Sandler | Maintains | Neutral → Neutral | — | $246.27 | $245.67 | -0.2% | -0.5% | +0.0% | -1.6% | +1.5% | +0.7% |
| Feb 7 | Barclays | Maintains | Equal Weight → Equal Weight | — | $247.74 | $248.88 | +0.5% | -0.6% | -0.5% | +0.0% | -1.6% | +1.5% |
| Feb 6 | Jefferies | Maintains | Buy → Buy | — | $249.99 | $252.98 | +1.2% | -0.9% | -0.6% | -0.5% | +0.0% | -1.6% |
| Feb 3 | Barclays | Maintains | Equal Weight → Equal Weight | — | $249.80 | $248.22 | -0.6% | -0.8% | -0.5% | +1.3% | -0.9% | -0.6% |
| Jan 28 | UBS | Maintains | Buy → Buy | — | $249.67 | $249.59 | -0.0% | -0.5% | -0.9% | +2.2% | -0.7% | -0.8% |
| Jan 7 | Evercore ISI | Upgrade | In Line → Outperform | — | $229.92 | $232.51 | +1.1% | +2.3% | -0.3% | -1.0% | +0.9% | +0.2% |
| Dec 17 | Morgan Stanley | Maintains | Overweight → Overweight | — | $229.62 | $228.57 | -0.5% | +0.6% | -2.0% | +0.3% | +0.7% | -0.3% |
| Dec 13 | BofA Securities | Maintains | Buy → Buy | — | $231.84 | $231.35 | -0.2% | +0.1% | -1.0% | +0.6% | -2.0% | +0.3% |
| Oct 30 | HSBC | Upgrade | Hold → Buy | — | $228.09 | $229.68 | +0.7% | +1.1% | -1.0% | -0.5% | +0.0% | +0.9% |
| Oct 28 | Piper Sandler | Maintains | Neutral → Neutral | — | $228.63 | $230.25 | +0.7% | -0.5% | +0.3% | +1.1% | -1.0% | -0.5% |
| Oct 25 | Baird | Maintains | Outperform → Outperform | — | $230.07 | $229.28 | -0.3% | -0.6% | -0.5% | +0.3% | +1.1% | -1.0% |
| Oct 25 | Barclays | Maintains | Equal Weight → Equal Weight | — | $230.07 | $229.28 | -0.3% | -0.6% | -0.5% | +0.3% | +1.1% | -1.0% |
| Aug 5 | BofA Securities | Maintains | Buy → Buy | — | $236.00 | $232.00 | -1.7% | -3.1% | -1.2% | -2.9% | +2.5% | +0.8% |
| Aug 2 | Baird | Maintains | Outperform → Outperform | — | $233.39 | $232.70 | -0.3% | +1.1% | -3.1% | -1.2% | -2.9% | +2.5% |
| Aug 2 | UBS | Maintains | Buy → Buy | — | $233.39 | $232.70 | -0.3% | +1.1% | -3.1% | -1.2% | -2.9% | +2.5% |
| Aug 2 | Deutsche Bank | Maintains | Hold → Hold | — | $233.39 | $232.70 | -0.3% | +1.1% | -3.1% | -1.2% | -2.9% | +2.5% |
| Aug 2 | Barclays | Maintains | Equal Weight → Equal Weight | — | $233.39 | $232.70 | -0.3% | +1.1% | -3.1% | -1.2% | -2.9% | +2.5% |
| Aug 2 | Truist | Maintains | Buy → Buy | — | $233.39 | $232.70 | -0.3% | +1.1% | -3.1% | -1.2% | -2.9% | +2.5% |
| Jul 9 | Evercore ISI | Maintains | In Line → In Line | — | $202.96 | $201.70 | -0.6% | -1.8% | +0.5% | +2.9% | -0.0% | +0.6% |
| Jul 8 | Baird | Maintains | Outperform → Outperform | — | $204.58 | $204.00 | -0.3% | -0.8% | -1.8% | +0.5% | +2.9% | -0.0% |
| Jun 13 | Baird | Maintains | Outperform → Outperform | — | $196.36 | $195.42 | -0.5% | +0.1% | +1.7% | +0.8% | +2.5% | +0.4% |
| May 30 | JP Morgan | Maintains | Overweight → Overweight | — | $192.50 | $192.51 | +0.0% | +0.5% | +0.8% | +0.1% | +0.9% | +0.7% |
| Apr 26 | Truist | Maintains | Buy → Buy | — | $198.35 | $197.08 | -0.6% | +0.0% | +2.9% | -1.4% | -0.0% | -0.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 8, 2026 | Kyle Kathryn WOff | EVP, Chief Legal Officer | Sell | 762 | $263.89 | $201K | 3,813 | -1.25% | -1.96% |
| May 11, 2026 | Schechter Adam HDir/Off | President & CEO | Sell | 5,903 | $254.50 | $1.5M | 107,234 | -0.16% | +1.47% |
8-K · 7.01
! Medium
Labcorp Holdings Inc. -- 8-K 7.01: Regulation FD Disclosure
Labcorp Holdings will present at the June 3 Jefferies Healthcare Conference, providing investors an opportunity to hear management discuss the company's laboratory services strategy and outlook.
May 27
8-K
Labcorp Holdings Inc. -- 8-K Filing
May 26
8-K · 8.01
!! High
Onconetix, Inc. -- 8-K 8.01: Material Event / Announcement
May 14
8-K
Labcorp Holdings Inc. -- 8-K Filing
Labcorp Holdings reported Q1 2026 results and raised full-year guidance, signaling confidence in its laboratory services business performance and providing updated investor expectations for 2026.
Apr 30
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
LabCorp declares a $0.72 quarterly dividend, demonstrating confidence in cash generation and shareholder returns, which typically supports stock valuation for income-focused investors.
Apr 9
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
LH scheduled Q1 2026 earnings release for April 30, 2026, signaling normal operational transparency; investors should monitor results for revenue growth and margin performance in diagnostic/laboratory services.
Mar 31
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Financing / Debt Agreement
Failure to meet covenant requirements could force accelerated repayment of debt, creating liquidity risk and potentially triggering financial distress if the company cannot refinance quickly.
Mar 20
8-K
Labcorp Holdings Inc. -- 8-K Filing
Labcorp exceeded expectations in 2025 with 7% revenue growth and double-digit adjusted EPS expansion, signaling operational strength entering 2026 despite ongoing healthcare sector challenges.
Feb 17
8-K · 5.02
!!! Very High
Labcorp Holdings Inc. -- 8-K 5.02: Executive Change
Labcorp Holdings appointed John H. Sampson as director effective February 9, 2026, potentially bringing fresh expertise to the board's oversight of the clinical laboratory company's operations.
Feb 9
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 5,376,120 | $1.4B | New | Mar 2026 |
| 2 | Victory Capital Management Inc | 4,627,126 | $1.2B | Reduced | Mar 2026 |
| 3 | Vanguard Portfolio Management Llc | 3,680,661 | $982M | New | Mar 2026 |
| 4 | Morgan Stanley | 3,011,078 | $755M | — | Dec 2025 |
| 5 | Boston Partners | 2,368,796 | $632M | Added | Mar 2026 |
| 6 | Allspring Global Investments Holdings, Llc | 2,226,446 | $607M | Added | Mar 2026 |
| 7 | Select Equity Group, L.p. | 2,110,779 | $530M | Added | Dec 2025 |
| 8 | Jpmorgan Chase & Co | 1,532,723 | $404M | Added | Mar 2026 |
| 9 | Invesco Ltd. | 1,316,197 | $351M | Reduced | Mar 2026 |
| 10 | Fmr Llc | 1,288,411 | $344M | Reduced | Mar 2026 |
| 11 | Diamond Hill Capital Management Inc | 1,260,116 | $316M | Reduced | Dec 2025 |
| 12 | Nordea Investment Management Ab | 1,045,142 | $276M | Added | Mar 2026 |
| 13 | Northern Trust Corp | 997,410 | $266M | Reduced | Mar 2026 |
| 14 | Royal Bank Of Canada | 820,442 | $219M | Added | Mar 2026 |
| 15 | Bank Of America Corp /de/ | 724,811 | $193M | — | Mar 2026 |
| 16 | Cooke & Bieler Lp | 674,021 | $180M | Reduced | Mar 2026 |
| 17 | Beck Mack & Oliver Llc | 616,631 | $165M | Reduced | Mar 2026 |
| 18 | Lord, Abbett & Co. Llc | 585,844 | $156M | Reduced | Mar 2026 |
| 19 | Ubs Group Ag | 564,529 | $151M | Added | Mar 2026 |
| 20 | Bank Of New York Mellon Corp | 536,388 | $143M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$22.15B
Enterprise Value
$27.46B
P/E (TTM)
23.60x
Forward P/E
15.13x
PEG Ratio
1.28x
P/B
2.60x
P/S
1.60x
P/FCF
18.77x
EV/EBITDA
13.31x
Shares Out
83.8M
Financials (TTM)
Revenue
$14.14B
Net Income
$941.5M
EBITDA
$2.06B
Free Cash Flow
$1.21B
Op Cash Flow
$1.64B
EPS Basic
$10.54
EPS Diluted
$11.29
EPS Forward
$17.86
Gross Margin
27.8%
Op Margin
11.0%
Net Margin
6.7%
Balance Sheet
Total Assets
$18.39B
Total Liab.
$9.76B
Total Equity
$8.64B
Cash
$532.3M
LT Debt
$5.77B
Book Value/Sh
$103.81
Debt/Equity
0.84x
Current Ratio
1.42
Quick Ratio
1.23
Returns & Growth
ROE
10.2%
ROA
4.8%
ROIC
7.4%
Rev Growth YoY
+7.2%
EPS Growth YoY
+18.6%
Price Returns
2W
+2.4%
1M
+1.3%
3M
-10.1%
6M
-3.2%
12M
+4.5%
Technicals
52W High
$293.72
52W Low
$241.81
50d MA
$260.76
200d MA
$267.24
RSI (14)
56.50
ATR (14)
$5.96
Beta
0.98
Avg Volume
591K
Dividends
Div Rate
$2.89
Div Yield
1.1%
Frequency
4
Ex-Div Date
May 29, 2026
Analyst Price Targets
Consensus
$308.67
High
$326.00
Low
$300.00
Median
$300.00
Data updated apr 25, 2026 7:05pm
· Source: financialmodelingprep.com